PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Webcasts|July 21, 2020
Effective Imaging for Identification and Sizing API Domains
Author(s)Thermo Fisher Scientific
Combining FTIR and Raman spectroscopy provides the insight needed to ensure appropriate distribution and concentration of APIs within tablets. Watch this webcast to learn more. Live: Tuesday, Jul. 21, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after final airing Jul. 21, 2021 Register free
Register free:
Event Overview:
The distribution of API in a pharmaceutical tablet is a critical factor in developing drugs that are effective when consumed. What’s the best way to figure that out?
The combination of Fourier-transform infrared (FTIR) and Raman spectroscopy with mapping is well-suited for identifying and sizing API domains. Both techniques provide excellent chemical and spatial information about the distribution and concentration of the API in a tablet.
Key Learning Objectives:
- How to collect area data in FTIR and Raman imaging
- How to process and analyze a large mapping/imaging data set
- Understand and interpret the data to communicate to stakeholders
Speakers: Mike Bradley, Product Manager, FTIR and FTIR Microscopy, Thermo Fisher Scientific
Matthew Kole, Product Manager, Raman Spectroscopy, Thermo Fisher Scientific
Time and Date: Tuesday, Jul. 21, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after final airing Jul. 21, 2021
Sponsor: Thermo Fisher Scientific
Register free:
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.